Springworks Therapeutics, Inc. (NASDAQ:SWTX) made its public debut Friday morning, opening at $24.50 after being priced between $16 and $18 per share.
The company's shares have been listed on the Nasdaq under the ticker symbol "SWTX."
Springworks Therapeutics IPO: What You Need To Know
Springworks, founded in August 2017, is a clinical-stage biopharma company applying a precision medicine approach to develop medicines for rare diseases and cancer. It has a differentiated portfolio of small molecule targeted oncology product candidates.
JPMorgan, Goldman Sachs, Cowen and Wedbush PacGrow are the underwriters for the offering.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
